10-Q quarterly report · filed Oct 29, 2026

CareDx, Inc. (CDNA) Q3 2026 10-Q Quarterly Report

Short answer

CareDx, Inc. (CDNA) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $139M (up 39.3% year over year) with net income of $19M.

Q3 2026 key financials · XBRL

Revenue
$139M
+39.3% YoY · +5.6% QoQ
Net income
$19M
+1051.8% YoY · −82.6% QoQ
Operating margin
5.8%
EPS (diluted)
$0.32
+966.7% YoY · −84.6% QoQ

Source: XBRL data from the CareDx, Inc. (CDNA) Q3 2026 10-Q on SEC EDGAR. USD.

CareDx, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $139.4M, up 39% YoY from $100.1M
  • Testing Services best performer: $119.2M, up 65% YoY; Product revenue worst, $0 vs $12.5M
  • Operating margin 5.8% vs (0.2)% YoY; net income $19.3M vs $1.7M
  • Operating cash flow $13M; nine-month cash $250.5M, with $164.8M sale proceeds and $145.8M Naveris acquisition
  • NavDx outlook sensitive to payer coverage, clinician adoption, competition and Naveris integration; up to $100.0M contingent consideration tied to 2026 and 2027 revenue milestones

Risk Factors

  • Newly emphasized AI risk: healthcare AI may produce inaccurate or biased outputs, triggering regulatory scrutiny, product complaints, recalls, or liability claims
  • Medicare reimbursement risk: 2027 preliminary rates show AlloSure rising from $2,753 to $2,840, but final CMS rates remain subject to revision
  • Regulatory compliance risk: FDA LDT oversight remains uncertain after 2025 rule reversal, potentially requiring additional studies and PMA or 510(k) submissions
  • Competitive risk: NavDx faces larger ctDNA competitors with broader oncology menus, stronger payer relationships, and greater resources
  • Financial risk: cash and equivalents totaled $250.5 million against a $486.2 million accumulated deficit, with additional capital potentially required

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CareDx, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.